TY - JOUR AU - Kassner, U. AU - Schlabs, T. AU - Rosada, A. PY - 2015 DA - 2015// TI - Lipoprotein(a)-An independent causal risk factor for cardiovascular disease and current therapeutic options JO - Atheroscler Suppl VL - 18 UR - https://doi.org/10.1016/j.atherosclerosissup.2015.02.039 DO - 10.1016/j.atherosclerosissup.2015.02.039 ID - Kassner2015 ER - TY - JOUR AU - Jacobson, T. A. PY - 2013 DA - 2013// TI - Lipoprotein(a). Cardiovascular Disease, and Contemporary Management JO - Mayo Clin Proc VL - 88 UR - https://doi.org/10.1016/j.mayocp.2013.09.003 DO - 10.1016/j.mayocp.2013.09.003 ID - Jacobson2013 ER - TY - JOUR AU - Nielsen, L. B. AU - Grønholdt, M. L. AU - Schroeder, T. V. PY - 1997 DA - 1997// TI - In vivo transfer of lipoprotein(a) into human atherosclerotic carotid arterial intima JO - Arterioscler Thromb Vasc Biol VL - 17 UR - https://doi.org/10.1161/01.ATV.17.5.905 DO - 10.1161/01.ATV.17.5.905 ID - Nielsen1997 ER - TY - JOUR AU - Erqou, S. AU - Kaptoge, S. AU - Perry, P. L. PY - 2009 DA - 2009// TI - Emerging Risk Factors Collaboration, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality JO - JAMA VL - 302 UR - https://doi.org/10.1001/jama.2009.1063 DO - 10.1001/jama.2009.1063 ID - Erqou2009 ER - TY - JOUR AU - Boffa, M. B. AU - Marcovina, S. M. AU - Koschinsky, M. L. PY - 2004 DA - 2004// TI - Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models JO - Clin Biochem VL - 37 UR - https://doi.org/10.1016/j.clinbiochem.2003.12.007 DO - 10.1016/j.clinbiochem.2003.12.007 ID - Boffa2004 ER - TY - JOUR AU - Yeang, C. AU - Witztum, J. L. AU - Tsimikas, S. PY - 2015 DA - 2015// TI - 'LDL-C' = LDL-C + Lp(a)-C: implications of achieved ultra-low LDL-C levels in the proprotein convertase subtilisin/kexin type 9 era of potent LDL-C lowering JO - Curr Opin Lipidol VL - 26 UR - https://doi.org/10.1097/MOL.0000000000000171 DO - 10.1097/MOL.0000000000000171 ID - Yeang2015 ER - TY - JOUR AU - Dubé, J. B. AU - Boffa, M. B. AU - Hegele, R. A. PY - 2012 DA - 2012// TI - Lipoprotein(a): more interesting than ever after 50 years JO - Curr Opin Lipidol VL - 23 UR - https://doi.org/10.1097/MOL.0b013e32835111d8 DO - 10.1097/MOL.0b013e32835111d8 ID - Dubé2012 ER - TY - JOUR AU - Ohira, T. AU - Schreiner, P. J. AU - Morrisett, J. D. PY - 2006 DA - 2006// TI - Lipoprotein(a) and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study JO - Stroke VL - 37 UR - https://doi.org/10.1161/01.STR.0000222666.21482.b6 DO - 10.1161/01.STR.0000222666.21482.b6 ID - Ohira2006 ER - TY - JOUR AU - Matthews, K. A. AU - Sowers, M. F. AU - Derby, C. A. PY - 2005 DA - 2005// TI - Ethnic differences in cardiovascular risk factor burden among middle-aged women: Study of Women's Health Across the Nation (SWAN) JO - Am Heart J VL - 149 UR - https://doi.org/10.1016/j.ahj.2004.08.027 DO - 10.1016/j.ahj.2004.08.027 ID - Matthews2005 ER - TY - JOUR AU - Lippi, G. AU - Guidi, G. PY - 2003 DA - 2003// TI - Lipoprotein(a): an emerging cardiovascular risk factor JO - Crit Rev Clin Lab Sci VL - 40 UR - https://doi.org/10.1080/713609328 DO - 10.1080/713609328 ID - Lippi2003 ER - TY - JOUR AU - Marcovina, S. M. AU - Albers, J. J. AU - Scanu, A. M. PY - 2000 DA - 2000// TI - Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a) JO - Clin Chem VL - 46 ID - Marcovina2000 ER - TY - JOUR AU - Nordestgaard, B. G. AU - Chapman, M. J. AU - Ray, K. PY - 2010 DA - 2010// TI - Lipoprotein(a) as a cardiovascular risk factor: current status JO - Eur Heart J VL - 31 UR - https://doi.org/10.1093/eurheartj/ehq386 DO - 10.1093/eurheartj/ehq386 ID - Nordestgaard2010 ER - TY - JOUR AU - Marcovina, S. M. AU - Koschinsky, M. L. AU - Albers, J. J. PY - 2003 DA - 2003// TI - Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions JO - Clin Chem VL - 49 UR - https://doi.org/10.1373/clinchem.2003.023689 DO - 10.1373/clinchem.2003.023689 ID - Marcovina2003 ER - TY - JOUR AU - Eckardstein, A. AU - Schulte, H. AU - Cullen, P. PY - 2001 DA - 2001// TI - Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk JO - J Am Coll Cardiol VL - 37 UR - https://doi.org/10.1016/S0735-1097(00)01126-8 DO - 10.1016/S0735-1097(00)01126-8 ID - Eckardstein2001 ER - TY - JOUR AU - Rouy, D. AU - Grailhe, P. AU - Nigon, F. PY - 1991 DA - 1991// TI - Lipoprotein(a) impairs generation of plasmin by fibrin-bound tissue-type plasminogen activator. In vitro studies in a plasma milieu JO - Arterioscler Thromb VL - 11 UR - https://doi.org/10.1161/01.ATV.11.3.629 DO - 10.1161/01.ATV.11.3.629 ID - Rouy1991 ER - TY - JOUR AU - Kamstrup, P. R. AU - Tybjærg-Hansen, A. AU - Nordestgaard, B. G. PY - 2013 DA - 2013// TI - Extreme lipoprotein(a) levels and improved cardiovascular risk prediction JO - J Am Coll Cardiol VL - 61 UR - https://doi.org/10.1016/j.jacc.2012.12.023 DO - 10.1016/j.jacc.2012.12.023 ID - Kamstrup2013 ER - TY - JOUR AU - Kamstrup, P. R. AU - Benn, M. AU - Tybjærg-Hansen, A. PY - 2008 DA - 2008// TI - Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study JO - Circulation VL - 117 UR - https://doi.org/10.1161/CIRCULATIONAHA.107.715698 DO - 10.1161/CIRCULATIONAHA.107.715698 ID - Kamstrup2008 ER - TY - JOUR AU - Willeit, P. AU - Kiechl, S. AU - Kronenberg, F. PY - 2014 DA - 2014// TI - Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study JO - J Am Coll Cardiol VL - 64 UR - https://doi.org/10.1016/j.jacc.2014.03.061 DO - 10.1016/j.jacc.2014.03.061 ID - Willeit2014 ER - TY - JOUR AU - Genest, J. PY - 2003 DA - 2003// TI - Lipoprotein disorders and cardiovascular risk JO - J Inherit Metab Dis VL - 26 UR - https://doi.org/10.1023/A:1024449603891 DO - 10.1023/A:1024449603891 ID - Genest2003 ER - TY - JOUR PY - 2002 DA - 2002// TI - Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report JO - Circulation VL - 106 ID - ref20 ER - TY - JOUR AU - Erqou, S. AU - Kaptoge, S. AU - Perry, P. L. PY - 2009 DA - 2009// TI - Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality JO - JAMA VL - 302 UR - https://doi.org/10.1001/jama.2009.1063 DO - 10.1001/jama.2009.1063 ID - Erqou2009 ER - TY - JOUR AU - Khera, A. V. AU - Everett, B. M. AU - Caulfield, M. P. PY - 2014 DA - 2014// TI - Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) JO - Circulation VL - 129 UR - https://doi.org/10.1161/CIRCULATIONAHA.113.004406 DO - 10.1161/CIRCULATIONAHA.113.004406 ID - Khera2014 ER - TY - JOUR AU - Kavousi, M. AU - Leening, M. J. AU - Nanchen, D. PY - 2014 DA - 2014// TI - Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort JO - JAMA VL - 311 UR - https://doi.org/10.1001/jama.2014.2632 DO - 10.1001/jama.2014.2632 ID - Kavousi2014 ER - TY - JOUR AU - Karmali, K. N. AU - Goff, D. C. AU - Ning, H. PY - 2014 DA - 2014// TI - A systematic examination of the 2013 ACC/AHA pooled cohort risk assessment tool for atherosclerotic cardiovascular disease JO - J Am Coll Cardiol VL - 64 UR - https://doi.org/10.1016/j.jacc.2014.06.1186 DO - 10.1016/j.jacc.2014.06.1186 ID - Karmali2014 ER - TY - JOUR AU - Sechi, L. A. AU - Kronenberg, F. AU - Carli, S. PY - 1997 DA - 1997// TI - Association of serum lipoprotein(a) levels and apolipoprotein(a) size polymorphism with target-organ damage in arterial hypertension JO - JAMA VL - 277 UR - https://doi.org/10.1001/jama.1997.03540450045033 DO - 10.1001/jama.1997.03540450045033 ID - Sechi1997 ER - TY - JOUR AU - Goff, D. C. AU - Lloyd-Jones, D. M. AU - Bennett, G. PY - 2014 DA - 2014// TI - 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines JO - Circulation VL - 129 UR - https://doi.org/10.1161/01.cir.0000437741.48606.98 DO - 10.1161/01.cir.0000437741.48606.98 ID - Goff2014 ER - TY - JOUR AU - Davidson, M. H. AU - Ballantyne, C. M. AU - Jacobson, T. A. PY - 2011 DA - 2011// TI - Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists JO - J Clin Lipidol VL - 5 UR - https://doi.org/10.1016/j.jacl.2011.07.005 DO - 10.1016/j.jacl.2011.07.005 ID - Davidson2011 ER - TY - JOUR AU - Anderson, T. J. AU - Gregoire, J. AU - Hegele, R. A. PY - 2013 DA - 2013// TI - 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult JO - Can J Cardiol VL - 29 UR - https://doi.org/10.1016/j.cjca.2012.11.032 DO - 10.1016/j.cjca.2012.11.032 ID - Anderson2013 ER - TY - JOUR AU - Luc, G. AU - Bard, J. M. AU - Arveiler, D. PY - 2002 DA - 2002// TI - Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study JO - Atherosclerosis VL - 163 UR - https://doi.org/10.1016/S0021-9150(02)00026-6 DO - 10.1016/S0021-9150(02)00026-6 ID - Luc2002 ER - TY - JOUR AU - Maher, V. M. AU - Brown, B. G. AU - Marcovina, S. M. PY - 1995 DA - 1995// TI - Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a) JO - JAMA VL - 274 UR - https://doi.org/10.1001/jama.1995.03530220037029 DO - 10.1001/jama.1995.03530220037029 ID - Maher1995 ER - TY - JOUR AU - Saeedi, R. AU - Li, M. AU - Allard, M. AU - Frohlich, J. PY - 2014 DA - 2014// TI - Marked effects of extreme levels of lipoprotein(a) on estimation of low-density lipoprotein cholesterol JO - Clin Biochem VL - 47 UR - https://doi.org/10.1016/j.clinbiochem.2014.04.023 DO - 10.1016/j.clinbiochem.2014.04.023 ID - Saeedi2014 ER - TY - JOUR AU - Li, K. M. AU - Wilcken, D. E. AU - Dudman, N. P. PY - 1994 DA - 1994// TI - Effect of serum lipoprotein(a) on estimation of low-density lipoprotein cholesterol by the Friedewald formula JO - Clin Chem VL - 40 ID - Li1994 ER - TY - JOUR AU - Cannon, C. P. AU - Blazing, M. A. AU - Giugliano, R. P. PY - 2015 DA - 2015// TI - Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes JO - N Engl J Med VL - 18;372 UR - https://doi.org/10.1056/NEJMoa1410489 DO - 10.1056/NEJMoa1410489 ID - Cannon2015 ER - TY - JOUR AU - Wissen, S. AU - Smilde, T. J. AU - Trip, M. D. PY - 2003 DA - 2003// TI - Long term statin treatment reduces lipoprotein(a) concentrations in heterozygous familial hypercholesterolaemia JO - Heart VL - 89 UR - https://doi.org/10.1136/heart.89.8.893 DO - 10.1136/heart.89.8.893 ID - Wissen2003 ER - TY - JOUR AU - Børresen, A. L. AU - Berg, K. AU - Dahlén, G. PY - 1981 DA - 1981// TI - The effect of Gemfibrozil on human serum apolipoproteins and on serum reserve cholesterol binding capacity (SRCBC) JO - Artery VL - 9 ID - Børresen1981 ER - TY - JOUR AU - Albers, J. J. AU - Slee, A. AU - O'Brien, K. D. PY - 2013 DA - 2013// TI - Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes) JO - J Am Coll Cardiol VL - 62 UR - https://doi.org/10.1016/j.jacc.2013.06.051 DO - 10.1016/j.jacc.2013.06.051 ID - Albers2013 ER - TY - JOUR PY - 2013 DA - 2013// TI - HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment JO - Eur Heart J VL - 34 ID - ref37 ER - TY - JOUR AU - Li, M. AU - Saeedi, R. AU - Rabkin, S. W. AU - Frohlich, J. PY - 2014 DA - 2014// TI - Dramatic lowering of very high Lp(a) in response to niacin JO - J Clin Lipidol VL - 8 UR - https://doi.org/10.1016/j.jacl.2014.03.006 DO - 10.1016/j.jacl.2014.03.006 ID - Li2014 ER - TY - JOUR AU - Lavigne, P. M. AU - Karas, R. H. PY - 2013 DA - 2013// TI - The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression JO - J Am Coll Cardiol VL - 61 UR - https://doi.org/10.1016/j.jacc.2012.10.030 DO - 10.1016/j.jacc.2012.10.030 ID - Lavigne2013 ER - TY - JOUR AU - Man, L. C. AU - Kelly, E. AU - Duffy, D. PY - 2015 DA - 2015// TI - Targeting lipoprotein (a): an evolving therapeutic landscape JO - Curr Atheroscler Rep VL - 17 UR - https://doi.org/10.1007/s11883-015-0502-0 DO - 10.1007/s11883-015-0502-0 ID - Man2015 ER - TY - JOUR AU - Koren, M. J. AU - Giugliano, R. P. AU - Raal, F. J. PY - 2014 DA - 2014// TI - Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation against LDL-C (OSLER) randomized trial JO - Circulation VL - 129 UR - https://doi.org/10.1161/CIRCULATIONAHA.113.007012 DO - 10.1161/CIRCULATIONAHA.113.007012 ID - Koren2014 ER - TY - STD TI - Juxtapid (lomitapide) capsules [package insert]. Cambridge, MA; Aegerion Pharmaceuticals. Revised August, 2014. ID - ref42 ER - TY - JOUR AU - Gotto, A. M. AU - Kher, U. AU - Chatterjee, M. S. PY - 2014 DA - 2014// TI - Lipids, safety parameters, and drug concentrations after an additional 2 years of treatment with anacetrapib in the DEFINE study JO - J Cardiovasc Pharmacol Ther VL - 19 UR - https://doi.org/10.1177/1074248414529621 DO - 10.1177/1074248414529621 ID - Gotto2014 ER - TY - STD TI - Graham MJ, Viney N, Crooke R, et al. Antisense Inhibition of Apolipoprotein(a) to Lower Plasma Lipoprotein(a) Levels in Humans. J Lipid Res. 2015 Nov 4. pii: jlr.R052258. [Epub ahead of print] ID - ref44 ER - TY - JOUR AU - Tsimikas, S. AU - Viney, N. J. AU - Hughes, S. G. PY - 2015 DA - 2015// TI - Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study JO - Lancet VL - 386 UR - https://doi.org/10.1016/S0140-6736(15)61252-1 DO - 10.1016/S0140-6736(15)61252-1 ID - Tsimikas2015 ER - TY - JOUR AU - Thompson, G. R. PY - 2008 DA - 2008// TI - Recommendations for the use of LDL apheresis JO - Atherosclerosis VL - 198 UR - https://doi.org/10.1016/j.atherosclerosis.2008.02.009 DO - 10.1016/j.atherosclerosis.2008.02.009 ID - Thompson2008 ER - TY - JOUR AU - Leebmann, J. AU - Roeseler, E. AU - Julius, U. PY - 2013 DA - 2013// TI - Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study JO - Circulation VL - 128 UR - https://doi.org/10.1161/CIRCULATIONAHA.113.002432 DO - 10.1161/CIRCULATIONAHA.113.002432 ID - Leebmann2013 ER - TY - JOUR AU - Safarova, M. S. AU - Ezhov, M. V. AU - Afanasieva, O. I. PY - 2013 DA - 2013// TI - Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography JO - Atheroscler Suppl VL - 14 ID - Safarova2013 ER - TY - JOUR AU - Dryander, M. AU - Fischer, S. AU - Passauer, J. AU - Muller, G. PY - 2013 DA - 2013// TI - Differences in the atherogenic risk of patients treated by lipoprotein apheresis according to their lipid pattern JO - Atheroscler Suppl VL - 14 ID - Dryander2013 ER -